rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
Status:
Terminated
Trial end date:
2020-08-29
Target enrollment:
Participant gender:
Summary
Patients with diseases requiring complement inhibition who have previously taken part in
Akari clinical trials and who wish to continue to receive rVA576 (Coversin) after their
active participation in the parent trial has completed and patients treated under
compassionate use or named patient arrangements who wish to continue on rVA576 (Coversin)
therapy.